Terms: = Kidney tumors AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Treatment
37 results:
1. Pazopanib stimulates senescence of renal carcinoma cells through targeting nuclear factor E2-related factor 2 (nrf2).
Wang X; Yang J; Li D; Teng L; Chen Y; Meng J; Yang C; Yin Z; Li C
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23689. PubMed ID: 38613465
[TBL] [Abstract] [Full Text] [Related]
2. Ononin triggers ferroptosis-mediated disruption in the triple negative breast cancer both in vitro and in vivo.
Gong G; Wan Y; Liu Y; Zhang Z; Zheng Y
Int Immunopharmacol; 2024 May; 132():111959. PubMed ID: 38554442
[TBL] [Abstract] [Full Text] [Related]
3. A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-nrf2-induced renal tumor growth through increased oxidative stress.
Rawat L; Balan M; Sasamoto Y; Sabarwal A; Pal S
Redox Biol; 2023 Dec; 68():102945. PubMed ID: 37898101
[TBL] [Abstract] [Full Text] [Related]
4. The deubiquitylating enzyme USP35 restricts regulated cell death to promote survival of renal clear cell carcinoma.
Wang S; Wang T; Zhang X; Cheng S; Chen C; Yang G; Wang F; Wang R; Zhang Q; Yang D; Zhang Y; Liu S; Qin H; Liu Q; Liu H
Cell Death Differ; 2023 Jul; 30(7):1757-1770. PubMed ID: 37173391
[TBL] [Abstract] [Full Text] [Related]
5. Germline (epi)genetics reveals high predisposition in females: a 5-year, nationwide, prospective Wilms tumour cohort.
Stoltze UK; Hildonen M; Hansen TVO; Foss-Skiftesvik J; Byrjalsen A; Lundsgaard M; Pignata L; Grønskov K; Tumer Z; Schmiegelow K; Brok JS; Wadt KAW
J Med Genet; 2023 Sep; 60(9):842-849. PubMed ID: 37019617
[TBL] [Abstract] [Full Text] [Related]
6. FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1/nrf2 signaling pathway.
Huang H; Zhang J; Jiang P; Xu X; Huang F; Zhao B; Wang X; Zhou L
Anticancer Drugs; 2023 Feb; 34(2):248-256. PubMed ID: 36730618
[TBL] [Abstract] [Full Text] [Related]
7. Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy.
Rustum YM; Reis R; Rustum TM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674417
[TBL] [Abstract] [Full Text] [Related]
8. YAP-Activated SATB2 Is a Coactivator of nrf2 That Amplifies Antioxidative Capacity and Promotes Tumor Progression in Renal Cell Carcinoma.
Jin J; Chen F; He W; Zhao L; Lin B; Zheng D; Chen L; He H; He Q
Cancer Res; 2023 Mar; 83(5):786-803. PubMed ID: 36598364
[TBL] [Abstract] [Full Text] [Related]
9. 5-Hydroxyeicosatetraenoic Acid Controls Androgen Reduction in Diverse Types of Human Epithelial Cells.
Hardaway AL; Goudarzi M; Berk M; Chung YM; Zhang R; Li J; Klein E; Sharifi N
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36412122
[TBL] [Abstract] [Full Text] [Related]
10. Silibinin ameliorates cisplatin-induced acute kidney injury via activating Nfe2l1-mediated antioxidative response to suppress the ROS/MAPK signaling pathway.
Yang F; Jia M; Deng C; Xiao B; Dai R; Xiang Y
J Mol Histol; 2022 Aug; 53(4):729-740. PubMed ID: 35727472
[TBL] [Abstract] [Full Text] [Related]
11. Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.
Murugan P; Jia L; Dinatale RG; Assel M; Benfante N; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Hakimi AA; Russo P; Chen YB; Tickoo SK; Reuter VE
Mod Pathol; 2022 Jun; 35(6):825-835. PubMed ID: 34949764
[TBL] [Abstract] [Full Text] [Related]
12. kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, nrf2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract] [Full Text] [Related]
13. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics.
Weng Q; Sun H; Fang C; Xia F; Liao H; Lee J; Wang J; Xie A; Ren J; Guo X; Li F; Yang B; Ling D
Nat Commun; 2021 Mar; 12(1):1436. PubMed ID: 33664241
[TBL] [Abstract] [Full Text] [Related]
14. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-nrf2 signaling in colorectal cancer cell.
Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
[TBL] [Abstract] [Full Text] [Related]
15. [Molecular mechanism analysis of Erzhi Wan in treatment of aging based on network pharmacology].
Shan S; Wang Q; Wang WL; Wu XY; Yan XJ; Liu HN
Zhongguo Zhong Yao Za Zhi; 2020 Jun; 45(12):2932-2937. PubMed ID: 32627469
[TBL] [Abstract] [Full Text] [Related]
16. Bisdemethoxycurcumin attenuates cisplatin-induced renal injury through anti-apoptosis, anti-oxidant and anti-inflammatory.
Jin F; Chen X; Yan H; Xu Z; Yang B; Luo P; He Q
Eur J Pharmacol; 2020 May; 874():173026. PubMed ID: 32088177
[TBL] [Abstract] [Full Text] [Related]
17. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Ooi A
Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
[TBL] [Abstract] [Full Text] [Related]
18. SP600125 enhances C-2-induced cell death by the switch from autophagy to apoptosis in bladder cancer cells.
Yu H; Wu CL; Wang X; Ban Q; Quan C; Liu M; Dong H; Li J; Kim GY; Choi YH; Wang Z; Jin CY
J Exp Clin Cancer Res; 2019 Nov; 38(1):448. PubMed ID: 31685029
[TBL] [Abstract] [Full Text] [Related]
19. tumors with TSC mutations are sensitive to CDK7 inhibition through nrf2 and glutathione depletion.
Zarei M; Du H; Nassar AH; Yan RE; Giannikou K; Johnson SH; Lam HC; Henske EP; Wang Y; Zhang T; Asara J; Kwiatkowski DJ
J Exp Med; 2019 Nov; 216(11):2635-2652. PubMed ID: 31506280
[TBL] [Abstract] [Full Text] [Related]
20. Progress of small ubiquitin-related modifiers in kidney diseases.
Li O; Ma Q; Li F; Cai GY; Chen XM; Hong Q
Chin Med J (Engl); 2019 Feb; 132(4):466-473. PubMed ID: 30707172
[TBL] [Abstract] [Full Text] [Related]
[Next]
